An independent clinical and laboratory study of more than 3000 people treated with the drug natalizumab (Tysabri®) for multiple sclerosis (MS), Crohns disease, and rheumatoid arthritis has found no evidence of new cases of the often-fatal disorder called progressive multifocal leukoencephalopathy (PML). The laboratory component of the study was coordinated by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), working in conjunction with the NIH Clinical Center. Clinical and neuroradiological experts from other institutions also participated. Results of the study will be published in the March 2, 2006, issue of the New England Journal of Medicine.*
Natalizumab, an immune system-modifying drug, was approved by the U.S. Food and Drug Administration in November 2004 to treat relapsing-remitting MS. Studies have shown that it can substantially reduce the frequency of relapses in that disease. However, the drug was withdrawn from the market and from clinical trials in February 2005 after the manufacturer identified 2 cases of PML in MS patients who had received the drug. A person with Crohns disease who had received natalizumab was also diagnosed with PML. The current study was conducted to determine whether other people treated with natalizumab were at risk of PML. Symptoms of PML include mental deterioration, problems with vision, speech, balance, and movement, and, in most cases, coma and death.
"This was an important opportunity for NIH to use its specialized expertise in cooperation with the private sector to address a pressing and unanticipated risk of a devastating disorder," said NIH Director Elias A. Zerhouni, M.D.
Natalie Frazin | EurekAlert!
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy